Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells in vitro and in vivo
Open accessAbstract
Overexpression of adenosine triphosphate (ATP)-binding cassette subfamily G member 2 (ABCG2) in cancer cells is known to cause multidrug resistance (MDR), which severely limits the clinical efficacy of chemotherapy. Currently, there is no FDA-approved MDR modulator for clinical use. In this study, rociletinib (CO-1686), a mutant-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was found to significantly improve the efficacy of ABCG2 substrate chemotherapeutic agents in the transporter-overexpressing cancer cells in vitro and in MDR tumor xenografts in nude mice, without incurring additional toxicity. Mechanistic studies revealed that in ABCG2-overexpressing cancer cells, rociletinib inhibited ABCG2-mediated drug efflux and increased intracellular accumulation of ABCG2 probe substrates. Moreover, rociletinib, inhibited the ATPase activity, and competed with [125I] iodoarylazidoprazosin (IAAP) photolabeling of ABCG2. However, ABCG2 expression at mRNA and protein levels was not altered in the ABCG2-overexpressing cells after treatment with rociletinib. In addition, rociletinib did not inhibit EGFR downstream signaling and phosphorylation of protein kinase B (AKT) and extracellular signal-regulated kinase (ERK). Our results collectively showed that rociletinib reversed ABCG2-mediated MDR by inhibiting ABCG2 efflux function, thus increasing the cellular accumulation of the transporter substrate anticancer drugs. The findings advocated the combination use of rociletinib and other chemotherapeutic drugs in cancer patients with ABCG2-overexpressing MDR tumors.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
At the April 2016 ODAC meeting, experts voted to delay approval of rociletinib, and Clovis announced the termination of rociletinib.
“Despite this, at the April 2016 ODAC meeting, experts voted to delay approval of rociletinib, and Clovis announced the termination of rociletinib.193”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [193]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · see citing works
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837 · see citing works
Carmichael, J., DeGraff, W., Gazdar, A. F., Minna, J. D., & Mitchell, J. B. (1987) · PubMed · Cited by 3,813 · see citing works
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643 · see citing works
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T. A., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,319 · see citing works
Epidermal growth factor receptor (EGFR) signaling in cancer
Normanno, N., Luca, A. D., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., Carotenuto, A., Feo, G. D., Caponigro, F., & Salomon, D. S. (2005) · Gene · doi:10.1016/j.gene.2005.10.018 · Cited by 2,035 · see citing works
Miyake, K., Mickley, L. A., Litman, T., Zhan, Z., Robey, R. W., Cristensen, B., Brangi, M., Greenberger, L., Dean, M. C., Fojo, T., et al. (1999) · PubMed · Cited by 819 · see citing works
Human ATP-binding cassette (ABC) transporter family
Vasiliou, V., Vasiliou, K., & Nebert, D. W. (2008) · Human Genomics · doi:10.1186/1479-7364-3-3-281 · Cited by 779 · see citing works
Sarkadi, B., Homolya, L., Szakács, G., & Váradi, A. (2006) · Physiological Reviews · doi:10.1152/physrev.00037.2005 · Cited by 726 · see citing works
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity.
Carmichael, J., DeGraff, W., Gazdar, A. F., Minna, J. D., & Mitchell, J. B. (1987) · PubMed · Cited by 700 · see citing works
Blocking of EGF-Dependent Cell Proliferation by EGF Receptor Kinase Inhibitors
Yaish, P., Gazit, A., Gilon, C., & Levitzki, A. (1988) · Science · doi:10.1126/science.3263702 · Cited by 587 · see citing works
Holland, I. B., & Blight, M. A. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2993 · Cited by 579 · see citing works
Litman, T., Brangi, M., Hudson, E., Fetsch, P. A., Abati, A. D., Ross, D. D., Miyake, K., Resau, J. H., & Bates, S. E. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.11.2011 · Cited by 538 · see citing works
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells
Knuefermann, C., Lü, Y., Liu, B., Jin, W., Liang, K., Wu, L., Schmidt, M., Mills, G. B., Mendelsohn, J. M., & Fan, Z. (2003) · Oncogene · doi:10.1038/sj.onc.1206394 · Cited by 452 · see citing works
Choudhuri, S., & Klaassen, C. D. (2006) · International Journal of Toxicology · doi:10.1080/10915810600746023 · Cited by 415 · see citing works
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance
Natarajan, K., Xie, Y., Baer, M. R., & Ross, D. D. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.002 · Cited by 408 · see citing works
Dai, C.-L., Tiwari, A. K., Wu, C.-P., Su, X.-D., Wang, S.-R., Liu, D.-G., Ashby, C. R., Huang, Y., Robey, R. W., Liang, Y.-J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0499 · Cited by 386 · see citing works
Self-citationMutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity
Robey, R. W., Honjo, Y., Morisaki, K., Nadjem, T., Runge, S., Risbood, M., Poruchynsky, M. S., & Bates, S. E. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601370 · Cited by 367 · see citing works
Mi, Y.-J., Liang, Y.-J., Huang, H.-B., Zhao, H.-Y., Wu, C.-P., Wang, F., Tao, L.-Y., Zhang, C.-Z., Dai, C.-L., Tiwari, A. K., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0111 · Cited by 337 · see citing works
Self-citationShi, Z., Peng, X.-X., Kim, I., Shukla, S., Si, Q.-S., Robey, R. W., Bates, S. E., Shen, T., Ashby, C. R., Fu, L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2686 · Cited by 315 · see citing works
Self-citationMultidrug resistance associated proteins in multidrug resistance
Sodani, K. S., Patel, A. S., Kathawala, R. J., & Chen, Z. (2011) · 癌症：英文版 · doi:10.5732/cjc.011.10329 · Cited by 304 · see citing works
Self-citationReese, M. J., Savina, P. M., Generaux, G. T., Tracey, H., Humphreys, J. E., Kanaoka, E., Webster, L. O., Harmon, K. A., Clarke, J. D., & Polli, J. W. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.048918 · Cited by 255 · see citing works
A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2)
Robey, R. W., Honjo, Y., van de Laar, A., et al. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(01)00308-x · Cited by 246 · see citing works
Nukaga, S., Yasuda, H., Tsuchihara, K., Hamamoto, J., Masuzawa, K., Kawada, I., Naoki, K., Matsumoto, S., Mimaki, S., Ikemura, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2359 · Cited by 179 · see citing works
Miyata, H., Takada, T., Toyoda, Y., Matsuo, H., Ichida, K., & Suzuki, H. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00518 · Cited by 146 · see citing works
Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance
Fu, L., Liang, Y.-J., Deng, L., Ding, Y. P., Chen, L., Ye, Y.-L., Yang, X., & Pan, Q. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0742-5 · Cited by 145 · see citing works
Self-citationShi, Z., Liang, Y.-J., Chen, Z., Wang, X., Wang, X., Ding, Y. P., Chen, L., Yang, X.-P., & Fu, L. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.1.2236 · Cited by 141 · see citing works
Self-citationA High-Throughput Cell-Based Assay for Inhibitors of ABCG2 Activity
Henrich, C. J., Bokesch, H. R., Dean, M. C., Bates, S. E., Robey, R. W., Goncharova, E. I., Wilson, J. A., & McMahon, J. B. (2006) · SLAS DISCOVERY · doi:10.1177/1087057105284576 · Cited by 134 · see citing works
Litman, T., Jensen, U., Hansen, A., Covitz, K.-M., Zhan, Z., Fetsch, P. A., Abati, A. D., Hansen, P. B., Horn, T. D., Skovsgaard, T., et al. (2002) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(02)00492-3 · Cited by 127 · see citing works
Dai, C.-L., Liang, Y.-J., Wang, Y.-S., Tiwari, A. K., Yan, Y., Wang, F., Chen, Z., Tong, X.-Z., & Fu, L. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.027 · Cited by 120 · see citing works
Self-citationMechanism of Action of Human P-glycoprotein ATPase Activity
Hrycyna, C. A., Ramachandra, M., Ambudkar, S. V., Ko, Y. H., Pedersen, P. L., Pastan, I. H., & Gottesman, M. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.27.16631 · Cited by 116 · see citing works
Peck, R. A., Hewett, J., Harding, M. W., Wang, Y., Chaturvedi, P. R., Bhatnagar, A., Ziessman, H. A., Atkins, F., & Hawkins, M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.3130 · Cited by 106 · see citing works
Shukla, S., Robey, R. W., Bates, S. E., & Ambudkar, S. V. (2006) · Biochemistry · doi:10.1021/bi060552f · Cited by 103 · see citing works
Zhou, W., Zhang, X., Cheng, C., Wang, F., Wang, X., Liang, Y.-J., To, K. K. W., Wang, Z., Huang, H., & Fu, L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01849.x · Cited by 100 · see citing works
Self-citationZheng, L.-S., Wang, F., Li, Y., Zhang, X., Chen, L., Liang, Y.-J., Dai, C.-L., Yan, Y., Tao, L.-Y., Mi, Y., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005172 · Cited by 92 · see citing works
Self-citationThe role of tyrosine phosphorylation in cell growth and disease.
Hunter, T. R. (2000) · PubMed · Cited by 91 · see citing works
Gandhi, L., Harding, M. W., Neubauer, M. A., et al. (2007) · Cancer · doi:10.1002/cncr.22492 · Cited by 89 · see citing works
Dey, A., Wong, E.-T., Kua, N., et al. (2008) · Cell Cycle · doi:10.4161/cc.7.23.7213 · Cited by 77 · see citing works
Zhang, J., Wu, H.-Y., Xia, X.-K., et al. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.9.4543 · Cited by 73 · see citing works
Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
Passaro, A., Guerini‐Rocco, E., Pochesci, A., Vacirca, D., Spitaleri, G., Catania, C., Rappa, A., Barberis, M. C. P., & de Marinis, F. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.003 · Cited by 73 · see citing works
Fox, E., Widemann, B. C., Pastakia, D. J., Chen, C. C., Yang, S. X., Cole, D. E., & Balis, F. M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2845-1 · Cited by 71 · see citing works
Li, Q., Wang, W., Xu, J., et al. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00487.x · Cited by 60 · see citing works
Wang, X.-K., To, K. K. W., Huang, L.-Y., Xu, J.-H., Yang, K., Wang, F., Huang, Z.-C., Ye, S., & Fu, L. (2014) · Oncotarget · doi:10.18632/oncotarget.2647 · Cited by 59 · see citing works
Self-citationChen, Z., Chen, Y., Xu, M., Chen, L., Zhang, X., To, K. K. W., Zhao, H., Wang, F., Xia, Z., Chen, X., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0939 · Cited by 53 · see citing works
Self-citationRochat, B. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909789056999 · Cited by 51 · see citing works
Liao, B.-C., Lin, C., Lee, J., & Yang, J. C. (2016) · Journal of Biomedical Science · doi:10.1186/s12929-016-0305-9 · Cited by 50 · see citing works
Wang, F., Mi, Y., Chen, X.-G., Wu, X.-P., Liu, Z., Chen, S. P., Liang, Y.-J., Cheng, C., To, K. K. W., & Fu, L.-W. (2012) · Molecular Medicine · doi:10.2119/molmed.2011.00444 · Cited by 50 · see citing works
Self-citationYang, K., Chen, Y., To, K. K. W., Wang, F., Li, D., Chen, L., & Fu, L. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.168 · Cited by 44 · see citing works
Self-citationProto, C., Imbimbo, M., Gallucci, R., Brissa, A., Signorelli, D., Vitali, M., Macerelli, M., Corrao, G., Ganzinelli, M., Greco, F. G., et al. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.10.16 · Cited by 37 · see citing works
Guo, X., To, K. K. W., Chen, Z., Wang, X., Zhang, J., Luo, M., Wang, F., Yan, S., & Fu, L. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0690-x · Cited by 36 · see citing works
Self-citationZhang, Z., Guo, X., To, K. K. W., Chen, Z., Fang, X., Luo, M., Ma, C., Xu, J., Yan, S., & Fu, L. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.06.002 · Cited by 27 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
Zhang, Y., Li, C., Xia, C., Wah To, K. K., Guo, Z., Ren, C., Wen, L., Wang, F., Fu, L., & Liao, N. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00955-8 · Cited by 33 · see citing works
Self-citation
- Authors
- Zeng, F., Wang, F., Zheng, Z., Chen, Z., Wah To, K. K., Zhang, H., Han, Q., & Fu, L.
- Affiliations
- Sun Yat-sen University (CN)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
- Corresponding author
- Zheng, Zongheng
- Fu, Liwu
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 10
- Issue
- 5
- Pages
- 799-811
- ISSN
- 2211-3835 (ISSN-L)
- PMC
- PMC7280144
- OpenAlex
- W3001778677
- Cited by
- 26
- References
- 51
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 9 · 2021: 5 · 2020: 2
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Acta Pharmaceutica Sinica B (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81673463)
- Science and Technology Major Project of Guangxi (2018ZX09711002-003-011)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Antibiotic Resistance in Bacteria
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- rociletinib, ABCG2, multidrug resistance, EGFR tyrosine kinase inhibitors, chemosensitization, drug accumulation, ATPase activity, MDR modulators, combination chemotherapy, tumor xenografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
